Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026
Biohaven's novel FGFR3-directed antibody-drug conjugate (ADC), BHV-1530, demonstrated promising clinical activity and confirmed responses in patients with FGFR3-altered urothelial cancer (UC) and head and neck squamous cell carcinoma (HNSCC) in an ongoing Phase 1 study. Data presented at ENA 2026 showed deep and durable responses, including in patients who failed prior standard-of-care therapies, with BHV-1530 being well tolerated and free from common FGFR tyrosine kinase inhibitor toxicities. Biohaven plans to initiate a pivotal study in FGFR3-altered tumors, starting with UC, in the first half of 2027 to support potential accelerated approval.
Biohaven cancer drug BHV-1530 shows responses in Phase 1 trial
Biohaven Ltd. reported positive Phase 1 clinical data for its investigational antibody-drug conjugate BHV-1530, showing tumor reduction and partial responses in patients with activating FGFR3 alterations, including those with urothelial cancer and HPV-positive head and neck squamous cell carcinoma. The drug demonstrated a favorable safety profile with no dose-limiting toxicities or treatment-related serious adverse events. Biohaven plans to initiate a pivotal study in FGFR3-altered tumors in the first half of 2027, aiming for potential accelerated approval.
An asset manager reports 2.04 million Biohaven (BHVN) shares across client portfolios.
Janus Henderson Group Ltd. has filed an amended passive investment disclosure (SCHEDULE 13G/A) indicating beneficial ownership of 2,036,197 common shares of Biohaven Ltd. (BHVN), which represents a 1.4% stake in the company. The asset manager exercises shared voting and dispositive power over these shares on behalf of its "Managed Portfolios" clients. These clients receive dividends and sale proceeds, with no single client owning more than 5% of Biohaven's common shares.
Biohaven (BHVN) Could Be 67% Undervalued After Graves Data And Ono Deal
Biohaven (BHVN) is gaining attention after presenting new Graves' disease data and announcing an international licensing deal with Ono Pharmaceutical. Despite recent mixed trading, analysts suggest the company could be 67% undervalued, with a fair value of $42.29, driven by optimistic trial outcomes for BHV-1300 and the potential for new revenue streams. However, ongoing cash burn and potential dilution are noted risks.
Will Graves Disease Trial Progress Change Biohaven (BHVN) Stock Narrative
Biohaven (BHVN) recently presented new clinical data at the 2026 American Thyroid Association meeting, highlighting Phase 3 progress for BHV-1300 in Graves' disease and preclinical results for BHV-1440. The company also secured an $80 million upfront licensing deal with Ono Pharmaceutical for its extracellular protein degradation platforms. This progress strengthens Biohaven's investment narrative, though the company faces challenges with funding and execution of its pivotal trials.
Is Biohaven (BHVN) Cheap As Pipeline Progress And The Ono Deal Lift Interest?
Biohaven (BHVN) has seen increased interest and share price growth following positive scientific and commercial updates, including new disease data and a US$80 million licensing deal with Ono Pharmaceutical. Despite a significant "undervalued" narrative suggesting a fair value of $42.29 compared to its current price of $14.48, the company faces risks such as ongoing cash burn, potential shareholder dilution, and a partial FDA hold on one of its candidates. The valuation relies on aggressive revenue growth forecasts and future profitability, which are yet to be realized given current losses.
Biohaven Ltd. (BHVN) Seasonal returns chart
The article provides a seasonal returns chart for Biohaven Ltd. (BHVN), detailing the average monthly price return from 2022 to 2026. It also shows current stock performance, with BHVN trading at 14.48 USD, up 4.17% at market close and an additional 0.69% in after-hours trading. The page also includes general market data for various indices and commodities.
How Pivotal Graves Trial Will Impact Biohaven Stock (BHVN)
Biohaven has commenced a pivotal Phase 3 trial for BHV-1300 in Graves' disease and secured an $80 million licensing deal with Ono Pharmaceutical for its MoDE degrader platform in parts of Asia. This clinical milestone and non-dilutive funding are crucial for the company, which is currently operating at a loss with limited cash reserves. Investors are evaluating Biohaven's ability to advance its immunology and neurology programs, as clinical execution remains key to its investment narrative and stock performance.
All 8 interviewed Graves’ patients with controlled thyroid levels still had symptoms
Biohaven is advancing its Graves' disease program with a Phase 3 pivotal trial for BHV-1300 and presented new scientific posters at the American Thyroid Association Annual Meeting. Early clinical results for BHV-1300 showed significant reduction in disease-driving antibodies and normalization of thyroid hormones. Patient interviews highlighted that even with controlled thyroid levels, most Graves' patients continue to experience significant symptoms and emotional impact, underscoring the need for new therapies that target the root cause of the disease.
Biohaven Ltd. Stock 12‑Month Price Target Raised to $25.67, Implies 56% Upside
Biohaven Ltd.'s average 12-month price target has been raised by analysts from $25.17 to $25.67, with forecasts ranging from $9 to $48 per share. This updated target suggests a potential upside of approximately 56% from the Oct. 29 closing price. The consensus rating for BHVN remains a "Buy" across 14 analysts.
Earnings Flash (BHVN) Biohaven Ltd. Posts Q3 Adjusted Loss $0.73 per Share, Vs. FactSet Est of $-0.78
Biohaven Ltd. (BHVN) announced an adjusted loss of $0.73 per share for the third quarter, which was better than the FactSet estimate of a $0.78 per share loss. This earnings report provides key financial performance data for the company.
Biohaven Ltd. Stock 12‑Month Price Target Raised to $25.67, Implies 56% Upside
Biohaven Ltd. (BHVN) has seen its average price target raised from $25.17 to $25.67 by 12 analysts, implying a potential 56% upside based on the October 29 closing price. The consensus rating for the stock remains "Buy," with 10 analysts recommending a Buy, 3 a Hold, and 1 a Sell out of 14 covering analysts.
Biohaven Reports Q3 2026 Results and $400 Million Kv7 License Agreement
Biohaven reported a Q3 2026 net loss of $129.3 million, or $0.86 per share, an improvement from $173.4 million a year earlier. The company also announced an exclusive global license agreement with SK Biopharmaceuticals for its Kv7 platform, and an exclusive license with Ono for its MoDE IgG degrader portfolio in specific Asian markets. Additionally, Biohaven provided updates on its clinical programs, including the FDA's acceptance of its resubmitted NDA for troriluzole.
Form 10-Q Biohaven Ltd. For: Sep 30
Biohaven Ltd. filed its Form 10-Q for the quarter ended September 30, 2026, detailing its financial condition and results of operations. The company reported a net loss of $129.279 million for the three months ended September 30, 2026, and $397.122 million for the nine months ended September 30, 2026, largely due to significant research and development expenses. Key developments include new out-licensing agreements for its Kv7 ion channel platform with SK Biopharmaceuticals and its MoDE pan IgG degrader portfolio with Ono Pharmaceutical Co., Ltd., as well as the FDA's acceptance of the NDA resubmission for Vyglxia (troriluzole) for spinocerebellar ataxia.
Biohaven Ltd. (BHVN) Posts Q3 Net Loss $129.3M; Adds $80M From Ono, Expects $350M From SKBP
Biohaven Ltd. (BHVN) reported a Q3 2026 net loss of $129.3 million ($0.86 per share) and held approximately $164.0 million in cash as of September 30. The company recently received $80.0 million from Ono and anticipates an additional $350.0 million from SK Biopharmaceuticals upon the closing of their deal. These significant partnership cash inflows are expected to extend Biohaven's financial runway and de-risk its funding.
An $80M license payment follows a narrower Q3 loss at Biohaven (BHVN).
Biohaven (BHVN) reported a narrower net loss of $129.3 million in Q3 2026, down from $173.4 million a year prior, and a nine-month net loss of $397.1 million compared to $593.3 million in 2025. The company recently secured an $80 million upfront payment from Ono Pharmaceutical Co., Ltd. for its MoDE IgG degrader portfolio and expects a $400 million upfront fee from SK Biopharmaceuticals Co., Ltd. for its Kv7 ion channel platform. Research and development expenses decreased significantly to $101.9 million in Q3 2026, from $141.2 million, due to strategic reprioritization of its programs.
Biohaven Ltd. (BHVN)
Biohaven Ltd. (BHVN) is currently trading at $15.29 USD, up 5.81% today. The company has a market cap of $2.31 billion and is estimated to release its next earnings report on November 9, 2026. Major holders include Citadel Advisors and Renaissance Technologies, though both have slightly decreased their positions recently.
Biohaven presents preclinical data for BHV-1420 kidney disease drug
Biohaven Ltd. (NYSE: BHVN) presented promising preclinical data for BHV-1420, an investigational drug for membranous nephropathy, at the American Society of Nephrology Kidney Week 2026 conference. The drug, part of Biohaven's TRAP extracellular protein degrader platform, is designed to degrade anti-PLA2R autoantibodies responsible for the disease. Preclinical tests showed significant reduction of these autoantibodies in patient samples and a mouse model, offering a potential new treatment given the limitations of current immunosuppressive therapies.
Biohaven’s previously rejected rare disease drug to get fresh FDA review
Biohaven's rare disease drug, Vyglxia, previously rejected by the FDA, will undergo a new review following a refreshed application with "new positive supportive analyses." The FDA's acceptance of the application and the scheduling of an advisory committee meeting have led to optimistic analyst notes and a 25% surge in Biohaven's shares, with a new verdict expected in the first quarter of next year. This marks a potential reversal given recent changes in FDA leadership and a stated desire for more flexibility in reviewing rare disease medicines.
Biohaven Ltd. Stock 12‑Month Price Target Raised to $24.92, Implies 112% Upside
Biohaven Ltd. (BHVN) has seen its average 12-month price target raised from $24.42 to $24.92 by 12 analysts, implying a potential upside of approximately 112% from its October 21st closing price. The consensus rating from 14 analysts remains "Buy," with 10 Buy ratings, 3 Holds, and 1 Sell.
Biohaven Ltd. Stock 12‑Month Price Target Raised to $24.92, Implies 112% Upside
Biohaven Ltd.'s average 12-month price target has been increased from $24.42 to $24.92, according to estimates from 12 analysts, implying a potential upside of 112% from its Oct. 21 closing price. The consensus rating for BHVN remains at "Buy" among 14 covering analysts, with 10 recommending Buy, 3 Hold, and 1 Sell.
Biohaven Shares Rise About 25% After FDA Accepts Resubmission
Biohaven Ltd. shares rose approximately 25% after the FDA accepted its resubmitted application for Vyglxia (troriluzole), an investigational treatment for spinocerebellar ataxia. The FDA set a user-fee goal date in the first quarter of 2027 and plans to convene an advisory committee, though no meeting date has been announced. The resubmission includes new supportive analyses, addressing previous concerns about the drug's effectiveness and study methodology.
Biohaven (BHVN) Jumps As Ono Deal Delivers Cash And Validation
Biohaven Ltd. (BHVN) surged after securing an exclusive deal with Ono Pharmaceutical, granting regional rights for its MoDE extracellular IgG degrader portfolio in several Asian territories. This partnership provides Biohaven with up to $100 million in non-dilutive funding and approximately 20% royalties, significantly extending its cash runway. The company also retains rights in major markets like the U.S., Europe, and China, and has upcoming catalysts with its BHV-1530 oncology program.
Why Is Biohaven Stock Soaring Today? - Biohaven (NYSE:BHVN)
Biohaven Ltd. (NYSE: BHVN) stock is significantly up today after the U.S. FDA accepted its new drug application resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia (SCA) for review, with a user fee goal date in the first quarter of 2027. Despite previous regulatory concerns regarding real-world evidence and a partial clinical hold on another program, the FDA considers the resubmission complete and plans to convene an advisory committee meeting. Analysts from William Blair previously noted that Biohaven shares could be undervalued if clinical programs succeed, maintaining a Market Perform rating while awaiting more controlled clinical data.
FDA accepts Biohaven's resubmitted troriluzole NDA for SCA with Q1 2027 goal date
The US FDA has accepted Biohaven's resubmitted new drug application for troriluzole (Vyglxia) to treat spinocerebellar ataxia (SCA), setting a user fee goal date in the first quarter of 2027. This resubmission addresses issues raised in a November 2025 Complete Response Letter, which cited concerns about real-world evidence and external control studies. The FDA plans to convene its Peripheral and Central Nervous System Advisory Committee to review the application, as there are currently no approved disease-modifying treatments for SCA.
Biohaven shares pop as FDA accepts resubmission for ataxia drug with adcomm expected
Biohaven's shares surged by 36% after the FDA accepted its resubmission for troriluzole, an ataxia drug previously rejected in 2025. The agency plans an advisory committee meeting and will make a decision in Q1 2027. This acceptance provides new hope for the rare disease, spinocerebellar ataxia, which currently lacks approved FDA therapies.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
This article details the pre-market movements of 12 health care stocks on Thursday, October 22, 2026. It identifies six top gainers, including Biohaven (BHVN) and Vogenx (VOGX), with significant percentage increases. The report also lists six top losers, such as Pomdoctor (POM) and China SXT Pharmaceuticals (SXTC), which saw notable declines.
Biohaven (BHVN) Jumps As Ono Deal Fuels Non-Dilutive Cash
Biohaven Ltd. (BHVN) saw its stock jump over 33% after securing a regional licensing deal with Ono Pharmaceutical. This agreement provides Biohaven with up to $100 million in near-term, non-dilutive funding for its MoDE IgG degrader portfolio, extending its financial runway. The deal, which grants Ono rights in Japan, South Korea, Taiwan, and Southeast Asia while Biohaven retains major Western markets, was well-received by traders, who also noted the upcoming plenary presentation for Biohaven's oncology asset BHV-1530.
Biohaven stock surges 25% on FDA acceptance of drug filing
Biohaven Ltd. shares surged 25% after the FDA accepted its resubmitted new drug application for troriluzole (Vyglxia) in spinocerebellar ataxia (SCA). The FDA considers the resubmission a complete response to a previous action letter and has set a user fee goal date in Q1 2027, with an advisory committee meeting planned. This marks a significant step forward for Biohaven in bringing the drug to market for this rare neurodegenerative disease.
FDA accepts Biohaven's troriluzole NDA resubmission for rare disease
Biohaven Ltd. announced that the U.S. Food and Drug Administration has accepted the new drug application resubmission for Vyglxia (troriluzole) to treat spinocerebellar ataxia (SCA). The FDA deemed the resubmission a complete response to a previous action letter and has set a user fee goal date in the first quarter of 2027, with plans to convene an advisory committee meeting. Troriluzole remains an investigational drug not yet approved in the United States.
RBC Capital Maintains Biohaven(BHVN.US) With Hold Rating, Maintains Target Price $19
RBC Capital has reiterated its Hold rating on Biohaven Pharmaceuticals (BHVN.US), maintaining a target price of $19 per share. This rating indicates the firm's current neutral outlook on the company's stock performance.
Biohaven Licenses IgG Degrader Portfolio to Ono Pharmaceutical for $80M Upfront, 20% Royalties
Biohaven has entered into a Collaboration and License Agreement with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio, including BHV-1300. The deal involves an $80 million upfront payment, a $20 million milestone, and approximately 20% royalties on net sales in Japan, South Korea, Taiwan, and ASEAN countries. Ono will handle local development and commercialization, while Biohaven retains rights outside this territory and will continue global studies with cost sharing.
Did Licensing Deal Just Shift Biohaven (BHVN) Investment Narrative?
Biohaven Ltd. has entered into a licensing and collaboration agreement with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio in Asian markets, including upfront payments and royalties. This deal is expected to ease Biohaven's funding needs and spread development costs, although the company remains pre-revenue and faces significant trial risks. The agreement supports Biohaven's pure execution investment narrative, focusing on pipeline progression and cash discipline.
Did Licensing Deal Just Shift Biohaven (BHVN) Investment Narrative?
Biohaven Ltd. recently signed a licensing deal with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio in Asian markets, securing up to $100 million in near-term payments and future royalties. This agreement is crucial for Biohaven, a pre-revenue company with limited cash, as it spreads development costs and provides a new revenue stream, easing financial pressures and potentially reshaping its investment narrative by reducing trial spending in Asia while preserving rights in major global markets. The deal supports Biohaven's broad pipeline development, though trial risks remain.
Eyes on Asia: TCGX, Biohaven, Roche
This article highlights key biopharma and healthcare dealmaking activities in Asia for the week ending October 11, 2026. TCGX closed an oversubscribed $600 million Asia fund, Biohaven licensed its IgG degrader portfolio to Ono Pharmaceutical for up to $200 million, and Roche partnered with Defand Therapeutics for molecular glue degraders in cancer and immune diseases. These developments underscore the growing importance and innovation within the Asian biotechnology ecosystem.
Ono Pharmaceutical (TSE:4528) Secures Biohaven Asia Rights, Is The Stock Still A Bargain?
Ono Pharmaceutical secured exclusive rights to Biohaven's MoDE pan IgG degrader drugs in Asia, causing its share price to ease despite strong one-year gains. The article analyzes Ono's valuation, noting a P/E of 13.9x, which is undervalued based on its DCF estimate, despite forecasts of declining earnings and revenue. The mixed signals suggest the need for investors to conduct their own thorough research.
How Biohaven Licensing Deal At Ono Pharmaceutical Stock Has Changed Its Investment Story
Ono Pharmaceutical has secured exclusive rights from Biohaven to develop and commercialize its MoDE pan IgG degrader portfolio across Japan, South Korea, Taiwan, and ASEAN markets. This deal provides Ono Pharmaceutical with access to a new platform for autoimmune diseases and gives Biohaven up to $100 million in near-term payments plus 20% royalties on future net sales. The agreement is expected to refresh Ono Pharmaceutical's medium-term catalyst list and deepen its pipeline, potentially influencing its broader investment narrative despite existing market forecasts for modest revenue declines.
Biohaven partners with Ono in $100m IgG degrader deal
Biohaven has signed an exclusive regional collaboration and licensing agreement with Ono Pharmaceutical for its MoDE pan immunoglobulin G (IgG) degrader portfolio, potentially worth up to $100 million. This deal grants Ono development and commercialization rights for drug candidates BHV-1300, BHV-1310, and BHV-1320 in ASEAN countries, Taiwan, South Korea, and Japan, with Biohaven retaining rights for other international markets. The lead candidate, BHV-1300, is a small-molecule degrader currently in Phase III trials for Graves’ disease.
Biohaven (BHVN), What Is Behind The Fresh Attention?
Biohaven (BHVN) has garnered fresh attention due to a regional licensing deal with Ono Pharmaceutical and an expanded oncology collaboration with Regeneron, despite recent weakness in its share price. The company is considered 69% undervalued by its most followed valuation narrative, with a fair value of $38.35 against a last close of $11.88. However, an opakalim clinical hold and high cash burn for late-stage trials pose risks to this narrative, and its P/B ratio suggests potential valuation risk compared to peers.
Biohaven Licenses IgG Degrader Portfolio to Ono for $80 Million Upfront
Biohaven Ltd. has licensed its IgG degrader portfolio to Ono Pharmaceutical for development and commercialization in Japan, South Korea, Taiwan, and ASEAN countries. The deal includes an $80 million upfront payment, a potential $20 million milestone, and approximately 20% royalties on net sales. The lead candidate, BHV-1300, is in Phase 3 trials for Graves' disease, with two follow-on candidates also part of the agreement, strengthening Ono's immunology pipeline.
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven Ltd. has signed a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize its MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan, and ASEAN countries. Biohaven will receive up to $100 million in near-term payments, including an $80 million upfront payment, and approximately 20% royalties on net sales. The agreement focuses on BHV-1300, a drug candidate in Phase 3 clinical development for Graves’ disease, with potential for other autoimmune conditions.
Biohaven licenses IgG degrader portfolio to Ono for USD 80 million upfront
Biohaven Ltd. has granted an exclusive license to Ono Pharmaceutical Co., Ltd. for its MoDE pan-IgG degrader portfolio, including BHV-1300, for development and commercialization in Japan, South Korea, Taiwan, and ASEAN states. The deal involves an $80 million upfront payment, up to $20 million in milestone payments, and approximately 20% royalties on net sales. BHV-1300 is currently in a pivotal Phase III trial for Graves' disease, having previously shown significant reduction in pathogenic autoantibodies in a Phase Ib study.
Ono Pharma inks license agreement with Biohaven
Japan's Ono Pharmaceutical has entered into an exclusive license agreement with US biopharma Biohaven for the development and commercialization of Biohaven’s IgG degrader portfolio in Japan, South Korea, Taiwan, and ASEAN countries. This portfolio includes BHV-1300, BHV-1310, and BHV-1320, which are novel small-molecule therapeutics targeting autoimmune diseases by selectively eliminating disease-causing autoantibodies. BHV-1300, the lead program, is currently in global Phase III development for Graves' disease.
Raymond James reiterates Strong Buy on Biohaven stock after Japan deal
Raymond James has reiterated a Strong Buy rating and a $30.00 price target for Biohaven Pharma (NYSE:BHVN) following a licensing agreement with Ono Pharma for IgG degrader BHV-1300 in Japan. This deal provides Biohaven with $100 million in near-term cash, extending its cash runway into 2029 and supporting the anticipated U.S. launch of BHV-1300. Despite a recent partial clinical hold on another program, Baird also reiterated an Outperform rating, though RBC Capital downgraded the stock due to its significant price increase.
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven Ltd. has signed a strategic licensing agreement with Ono Pharmaceutical Co., Ltd. for its MoDE pan IgG degrader portfolio, including lead candidate BHV-1300, for development and commercialization in Japan, South Korea, Taiwan, and ASEAN nations. Biohaven will receive up to $100 million in near-term payments and royalties on net sales, while retaining rights in other regions like the US, Europe, and China. BHV-1300 is currently in Phase 3 development for Graves' disease and has shown promising results in earlier trials.
Biohaven's BHV-1530 cancer drug selected for ENA 2026 presentation
Biohaven announced that its cancer drug BHV-1530, an FGFR3-directed antibody-drug conjugate, has been selected for an oral presentation at the ENA 2026 conference in November 2026. Early Phase 1 clinical data showed confirmed partial responses in heavily pretreated patients with advanced solid tumors, with no dose-limiting toxicities. The company has also entered a clinical supply agreement with Regeneron Pharmaceuticals to evaluate BHV-1530 in combination with cemiplimab.
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven Ltd. announced that clinical data for its novel FGFR3-directed antibody-drug conjugate (ADC) BHV-1530, which utilizes a proprietary TopoIx payload, has been selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium in November 2026. The Phase 1 findings demonstrate early clinical activity and a differentiated, tolerable safety profile, with confirmed partial responses observed in heavily pretreated patients. Biohaven has also initiated enrollment for a combination study of BHV-1530 with cemiplimab (Libtayo) under a clinical supply agreement with Regeneron Pharmaceuticals.
Biohaven’s cancer drug data selected for presentation at symposium
Biohaven Ltd. (NYSE:BHVN) announced that Phase 1 data for its antibody-drug conjugate, BHV-1530, targeting FGFR3, will be presented at the 38th EORTC-NCI-AACR Symposium. The data from the ongoing BHV1530-101 study showed early clinical activity, including confirmed partial responses in heavily pretreated patients, with no dose-limiting toxicities. Biohaven has also partnered with Regeneron Pharmaceuticals, Inc. to evaluate BHV-1530 in combination with cemiplimab for solid tumors.
Biohaven Presents BHV-1530 Phase 1 Study Findings at EORTC-NCI-AACR Symposium
Biohaven is presenting Phase 1 study findings for its drug BHV-1530 at the EORTC-NCI-AACR Symposium, highlighting early clinical activity and a favorable safety profile in heavily pretreated cancer patients. The company has also partnered with Regeneron to study BHV-1530 in combination with cemiplimab, aiming to enhance antitumor immune responses. BHV-1530 is the first FGFR3-targeted ADC, designed to address FGFR3-driven cancers, with ongoing trials expected to provide new treatment options and strengthen Biohaven's market position.
Biohaven (BHVN) Gains Attention As Pipeline Hopes Meet A Big Fair Value Gap
Biohaven (BHVN) has seen recent stock price movement, with a 4.41% 1-day return and a 12.50% 7-day return, despite ongoing losses and zero revenue. The company trades at a significant discount to its intrinsic value estimate of $70.05 per share according to a DCF model, but its price-to-book ratio is very high compared to peers, highlighting a mixed valuation picture. Investors are weighing the pipeline potential against substantial execution and funding risks, including a short cash runway and recent shareholder dilution.